| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1002/DDR.21673 |
| P698 | PubMed publication ID | 32329098 |
| P50 | author | C. Benjamin Naman | Q85961322 |
| T P Sajeevan | Q90444924 | ||
| Krishnankutty Chandrika Sivakumar | Q93202750 | ||
| P2093 | author name string | Jin Haixiao | |
| P2860 | cites work | CHARMM: the biomolecular simulation program | Q24658108 |
| Computational methods in drug discovery | Q26997089 | ||
| Established and emerging trends in computational drug discovery in the structural genomics era | Q27011910 | ||
| Shifting from the single to the multitarget paradigm in drug discovery | Q27144242 | ||
| DOCK 4.0: Search strategies for automated molecular docking of flexible molecule databases | Q27231136 | ||
| Altered brain energetics induces mitochondrial fission arrest in Alzheimer's Disease | Q27302961 | ||
| AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading | Q27860652 | ||
| Modelling protein docking using shape complementarity, electrostatics and biochemical information | Q28249132 | ||
| eHiTS: a new fast, exhaustive flexible ligand docking system | Q28253448 | ||
| Prospect of a dopamine contribution in the next generation of antidepressant drugs: the triple reuptake inhibitors | Q28256136 | ||
| Computer-aided drug design: the next 20 years | Q28256647 | ||
| Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial | Q28268831 | ||
| Sunitinib versus interferon alfa in metastatic renal-cell carcinoma | Q28282757 | ||
| Multi-target drugs: the trend of drug research and development | Q28480888 | ||
| Merck molecular force field. I. Basis, form, scope, parameterization, and performance of MMFF94 | Q28842789 | ||
| ICM?A new method for protein modeling and design: Applications to docking and structure prediction from the distorted native conformation | Q29010774 | ||
| Development and testing of a general amber force field | Q29547642 | ||
| A semiempirical free energy force field with charge-based desolvation | Q29614316 | ||
| Dynamic personalities of proteins | Q29616723 | ||
| Empirical scoring functions for advanced protein-ligand docking with PLANTS. | Q51857293 | ||
| Validation studies of the site-directed docking program LibDock. | Q51901678 | ||
| Knowledge-based scoring function to predict protein-ligand interactions. | Q52083236 | ||
| Consensus scoring: A method for obtaining improved hit rates from docking databases of three-dimensional structures into proteins. | Q52132563 | ||
| Hammerhead: fast, fully automated docking of flexible ligands to protein binding sites. | Q52304046 | ||
| Ligand docking to proteins with discrete side-chain flexibility. | Q52383197 | ||
| General and targeted statistical potentials for protein-ligand interactions. | Q52981145 | ||
| Multitarget Drug Discovery and Polypharmacology. | Q53376374 | ||
| Empirical scoring functions: I. The development of a fast empirical scoring function to estimate the binding affinity of ligands in receptor complexes. | Q53678858 | ||
| Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function | Q56885198 | ||
| Bridging Molecular Docking to Molecular Dynamics in Exploring Ligand-Protein Recognition Process: An Overview | Q58719254 | ||
| Can you teach old drugs new tricks? | Q59080940 | ||
| Phase Transition for a Hard Sphere System | Q60395801 | ||
| On the use of LUDI to search the Fine Chemicals Directory for ligands of proteins of known three-dimensional structure | Q72593914 | ||
| Thermodynamic contributions of the ordered water molecule in HIV-1 protease | Q73442110 | ||
| The physicochemical challenges of designing multiple ligands | Q80048530 | ||
| A QXP-based multistep docking procedure for accurate prediction of protein-ligand complexes | Q83372797 | ||
| Targeting multiple kinases in glioblastoma multiforme | Q83395665 | ||
| Challenges and opportunities of drug repositioning | Q86587232 | ||
| Supervised Molecular Dynamics (SuMD) Approaches in Drug Design | Q90434913 | ||
| Ginkgolic Acid is a Multi-Target Inhibitor of Key Enzymes in Pro-Inflammatory Lipid Mediator Biosynthesis | Q92403172 | ||
| Novel promising 4-anilinoquinazoline-based derivatives as multi-target RTKs inhibitors: Design, molecular docking, synthesis, and antitumor activities in vitro and vivo | Q93130382 | ||
| Development and Testing of the OPLS All-Atom Force Field on Conformational Energetics and Properties of Organic Liquids | Q99192955 | ||
| SODOCK: swarm optimization for highly flexible protein-ligand docking. | Q51091845 | ||
| Scoring ligand similarity in structure-based virtual screening. | Q51806309 | ||
| Binding estimation after refinement, a new automated procedure for the refinement and rescoring of docked ligands in virtual screening. | Q51829468 | ||
| Improved protein-ligand docking using GOLD | Q29616787 | ||
| The MARTINI force field: coarse grained model for biomolecular simulations | Q29617215 | ||
| Glide: a new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening | Q29617343 | ||
| Monte Carlo replica-exchange based ensemble docking of protein conformations | Q30398315 | ||
| From in silico target prediction to multi-target drug design: current databases, methods and applications | Q30403222 | ||
| FLOG: a system to select 'quasi-flexible' ligands complementary to a receptor of known three-dimensional structure | Q30420637 | ||
| Ligand binding to proteins: the binding landscape model | Q30428684 | ||
| Novel paradigms for drug discovery: computational multitarget screening | Q30662767 | ||
| High-throughput docking for lead generation | Q30663788 | ||
| Molecular recognition and docking algorithms | Q31130825 | ||
| Combining docking and molecular dynamic simulations in drug design | Q33245994 | ||
| pso@autodock: a fast flexible molecular docking program based on Swarm intelligence | Q33305123 | ||
| Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia | Q33387517 | ||
| Ginkgolic acid inhibits protein SUMOylation by blocking formation of the E1-SUMO intermediate | Q33412950 | ||
| Current combination chemotherapy regimens for metastatic breast cancer | Q33516194 | ||
| A phase II study of flavopiridol (Alvocidib) in combination with docetaxel in refractory, metastatic pancreatic cancer | Q33739625 | ||
| Targeting the cancer kinome through polypharmacology | Q33893019 | ||
| Integrating structure-based and ligand-based approaches for computational drug design | Q33893108 | ||
| Computer-aided identification of Trypanosoma brucei uridine diphosphate galactose 4'-epimerase inhibitors: toward the development of novel therapies for African sleeping sickness | Q33954211 | ||
| Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect | Q34022149 | ||
| Synthesis, biological evaluation, and molecular modeling of donepezil and N-[(5-(benzyloxy)-1-methyl-1H-indol-2-yl)methyl]-N-methylprop-2-yn-1-amine hybrids as new multipotent cholinesterase/monoamine oxidase inhibitors for the treatment of [...] | Q34056563 | ||
| Molecular dynamics simulations and drug discovery | Q34061019 | ||
| Polypharmacology: drug discovery for the future | Q34319906 | ||
| Advances and challenges in protein-ligand docking | Q34377911 | ||
| The GROMOS software for biomolecular simulation: GROMOS05. | Q34457783 | ||
| A new force field (ECEPP-05) for peptides, proteins, and organic molecules | Q34565535 | ||
| Development and validation of a modular, extensible docking program: DOCK 5. | Q34588100 | ||
| Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancer | Q34613941 | ||
| ABT-869, a multitargeted receptor tyrosine kinase inhibitor: inhibition of FLT3 phosphorylation and signaling in acute myeloid leukemia | Q35751114 | ||
| From magic bullets to designed multiple ligands | Q35848618 | ||
| Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics | Q35848830 | ||
| Multiple target drug cocktail design for attacking the core network markers of four cancers using ligand-based and structure-based virtual screening methods | Q35872435 | ||
| Multi-functional drugs for various CNS targets in the treatment of neurodegenerative disorders | Q35998174 | ||
| How to develop a successful cancer drug--molecules to medicines or targets to treatments? | Q36069293 | ||
| Target flexibility in molecular recognition | Q36266696 | ||
| Designed multiple ligands. An emerging drug discovery paradigm | Q36284452 | ||
| Molecular dynamics: survey of methods for simulating the activity of proteins | Q36472758 | ||
| Antileukemic effects of the novel, mutant FLT3 inhibitor NVP-AST487: effects on PKC412-sensitive and -resistant FLT3-expressing cells | Q37003553 | ||
| Multi-target-directed ligands to combat neurodegenerative diseases | Q37052982 | ||
| Pazopanib, a potent orally administered small-molecule multitargeted tyrosine kinase inhibitor for renal cell carcinoma | Q37071204 | ||
| Early clinical studies of novel therapies for thyroid cancers | Q37172796 | ||
| How many modes of action should an antibiotic have? | Q37214061 | ||
| Imatinib treatment for gastrointestinal stromal tumour (GIST). | Q37334993 | ||
| Designing multiple ligands - medicinal chemistry strategies and challenges | Q37387562 | ||
| Activity of the multikinase inhibitor dasatinib against ovarian cancer cells | Q37424063 | ||
| In-silico approaches to multi-target drug discovery : computer aided multi-target drug design, multi-target virtual screening | Q37707220 | ||
| The role of fragment-based and computational methods in polypharmacology. | Q37921883 | ||
| Polypharmacology in a single drug: multitarget drugs | Q38081536 | ||
| Protein-ligand docking in the new millennium--a retrospective of 10 years in the field | Q38093314 | ||
| Polypharmacology - foe or friend? | Q38126927 | ||
| Polypharmacology: challenges and opportunities in drug discovery | Q38221607 | ||
| Systems biology brings new dimensions for structure-based drug design | Q38233920 | ||
| In silico methods to address polypharmacology: current status, applications and future perspectives | Q38689965 | ||
| Computational Multitarget Drug Design. | Q38760828 | ||
| PSOVina: The hybrid particle swarm optimization algorithm for protein-ligand docking | Q39026290 | ||
| A comprehensive map of molecular drug targets. | Q39026969 | ||
| Antitumor activities of the targeted multi-tyrosine kinase inhibitor lenvatinib (E7080) against RET gene fusion-driven tumor models | Q39125714 | ||
| The inevitable QSAR renaissance | Q39681298 | ||
| The RET kinase inhibitor NVP-AST487 blocks growth and calcitonin gene expression through distinct mechanisms in medullary thyroid cancer cells | Q40105425 | ||
| A New Method for Navigating Optimal Direction for Pulling Ligand from Binding Pocket: Application to Ranking Binding Affinity by Steered Molecular Dynamics | Q40288332 | ||
| The in vitro and in vivo effects of JNJ-7706621: a dual inhibitor of cyclin-dependent kinases and aurora kinases | Q40365711 | ||
| CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma. | Q40480723 | ||
| A combination of cisplatin-eluting gelatin microspheres and flavopiridol enhances anti-tumour effects in a rabbit VX2 liver tumour model | Q41993498 | ||
| New pharmacological developments in the treatment of hepatocellular cancer | Q43234592 | ||
| Phase I and biomarker study of ABT-869, a multiple receptor tyrosine kinase inhibitor, in patients with refractory solid malignancies | Q43282879 | ||
| Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia | Q43899710 | ||
| Computational drug design accommodating receptor flexibility: the relaxed complex scheme | Q43992973 | ||
| Phase II study of flavopiridol in patients with advanced colorectal cancer | Q44525933 | ||
| A multiple-start Monte Carlo docking method. | Q44677796 | ||
| Water network perturbation in ligand binding: adenosine A(2A) antagonists as a case study. | Q44760042 | ||
| FlexX-Scan: fast, structure-based virtual screening | Q45070169 | ||
| In vivo target modulation and biological activity of CHIR-258, a multitargeted growth factor receptor kinase inhibitor, in colon cancer models | Q46173286 | ||
| CHIR-258: a potent inhibitor of FLT3 kinase in experimental tumor xenograft models of human acute myelogenous leukemia | Q46610628 | ||
| N-Methyl-N-((1-methyl-5-(3-(1-(2-methylbenzyl)piperidin-4-yl)propoxy)-1H-indol-2-yl)methyl)prop-2-yn-1-amine, a new cholinesterase and monoamine oxidase dual inhibitor. | Q48449256 | ||
| Deciphering the Complexity of Ligand-Protein Recognition Pathways Using Supervised Molecular Dynamics (SuMD) Simulations. | Q50525174 | ||
| P577 | publication date | 2020-04-23 | |
| P1433 | published in | Drug Development Research | Q15749332 |
| P1476 | title | Prospects of multitarget drug designing strategies by linking molecular docking and molecular dynamics to explore the protein-ligand recognition process |
| Q100430222 | Recent progress on cheminformatics approaches to epigenetic drug discovery | cites work | P2860 |
Search more.